12.03.12
A new study shows that ResistAid, a proprietary immune ingredient from Lonza, Basel Switzerland, has very good tolerability. The double-blind, randomized, placebo-controlled clinical trial was published in the November issue of the Food and Nutrition Sciences (Vol. 3, No. 11, p. 1533-1538), and was conducted by analyze & realize AG. The study interviewed a total of 199 healthy participants, who received either 4.5g ResistAid or placebo for a 12-week period. To examine tolerability based on safety parameters, the research recorded the number of adverse events and changes in various clinical and laboratory parameters, as well as the global evaluation of tolerability by investigators and subjects, as compared to placebo.
“The tolerability was rated as “very good” or “good” by the investigators for 99% of the subjects, and by 98 % of subjects in self-assessment with no statistical differences to placebo,” says Barbara Grube, M.D., coordinating investigator and lead author of the study. “There were no differences concerning the incidence of adverse events between the two groups. Therefore, the intake of ResistAid over a period of 12 weeks can be considered as safe as placebo.” For further information: http://www.scirp.org/journal/PaperInformation.aspx?paperID=24490
“The tolerability was rated as “very good” or “good” by the investigators for 99% of the subjects, and by 98 % of subjects in self-assessment with no statistical differences to placebo,” says Barbara Grube, M.D., coordinating investigator and lead author of the study. “There were no differences concerning the incidence of adverse events between the two groups. Therefore, the intake of ResistAid over a period of 12 weeks can be considered as safe as placebo.” For further information: http://www.scirp.org/journal/PaperInformation.aspx?paperID=24490